Tacrolimus for the treatment of active rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials

Scandinavian Journal of Rheumatology

Volumn 39, Issue 4, 2010, Pages 271-278

  Lee, Y H ^a   Woo, J H ^a   Choi, S J ^a   Ji, J D ^a   Bae, S C ^b   Song, G G ^a  

^a Korea University College of Medicine   (South Korea)

^b Hanyang University Hospital for Rheumatic Diseases   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; MIZORIBINE; PLACEBO; TACROLIMUS;

ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; META ANALYSIS; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMATIC REVIEW; THORAX PAIN;

ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TACROLIMUS; TREATMENT OUTCOME;

EID: 77954879792     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009740903501642     Document Type: Article

References (23)

1. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-1289
2. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001;134:695-706.
3. Kelly PA, Burckart GJ, Venkataramanan R. Tacrolimus: a new immunosuppressive agent. Am J Health Syst Pharm 1995;52:1521-1535
4. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987;40:1256-1265 (Pubitemid 17138110)
5. Tocci MJ, Matkovich DA, Collier KA, Kwok P, Dumont F, Lin S, et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 1989;143:718-726
6. Wiederrecht G, Lam E, Hung S, Martin M, Sigal N. The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci 1993;696:9-19.
7. Kawai S, Hashimoto H, Kondo H, Murayama T, Kiuchi T, Abe T. Comparison of tacrolimus and mizoribine in a randomized, double- blind controlled study in patients with rheumatoid arthritis. J Rheumatol 2006;33:2153-2161
8. Kondo H, Abe T, Hashimoto H, Uchida S, Irimajiri S, Hara M, et al. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. J Rheumatol 2004;31:243-251
9. Yocum DE, Furst DE, Kaine JL, Baldassare AR, Stevenson JT, Borton MA, et al. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. Arthritis Rheum 2003;48:3328-3337
10. Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T, et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum 2002;46:2020-2028
11. Kawai S, Yamamoto K. Safety of tacrolimus, an immunosuppres- sive agent, in the treatment of rheumatoid arthritis in elderly patients. Rheumatology (Oxford) 2006;45:441-444
12. Yocum DE, Furst DE, Bensen WG, Burch FX, Borton MA, Mengle- Gaw LJ, et al. Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology (Oxford) 2004;43:992-999
13. Kremer JM, Habros JS, Kolba KS, Kaine JL, Borton MA, Mengle-Gaw LJ, et al. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. Arthritis Rheum 2003;48:2763-2768
14. Gremillion RB, Posever JO, Manek N, West JP, van Volen-Hoven RF. Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis: initial experience in 12 patients. J Rheumatol 1999;26:2332-2336
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
16. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-ana- lysis detected by a simple, graphical test. Br Med J 1997;315:629-634
18. Davey Smith G, Egger M. Meta-analyses of randomised controlled trials. Lancet 1997;350:1182.
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta analysis. Stat Med 2002;21:1539-1558
20. Carli C, Bridges JF, Ask J, Lindblad S. Swedish Rheumatoid Arthritis Register. Charting the possible impact of national guidelines on the management of rheumatoid arthritis. Scand J Rheumatol 2008;37:188-193
21. Lee SS, Park YW, Park JJ, Kang YM, Nam EJ, Kim SI, et al. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. Scand J Rheuamtol 2009;38:11-14.
22. Nikolaisen C, Kvien TK, Mikkelsen K, Kaufmann C, Rodevand E, Nossent JC. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway. Scand J Rheuamtol 2009;19:1-6.
23. Liberati A, AltmanDG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62:e1-34.